BTIG Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $34

BTIG analyst Kambiz Yazdi initiates coverage on Kazia Therapeutics (NASDAQ: KZIA ) with a Buy rating and announces Price Target of $34.